Table 2.
Summary of study duration and immunoassay methods used in included publications
| Biologic/biosimilar | Number of publications | |||||||
|---|---|---|---|---|---|---|---|---|
| Study duration (week) | Immunoassay method | |||||||
| ≤24 | >24 | NR | ELISA | ECL | RIA | Other | NR | |
| ABA (n = 10) | 2 | 6 | 2 | 5 | 4 | 2 | ||
| ADA (n = 133) | 21 | 47 | 65 | 65 | 28 | 13 | 27 | |
| CZP (n = 22) | 8 | 12 | 2 | 13 | 2 | 7 | ||
| ETN (n = 61) | 11 | 26 | 24 | 34 | 1 | 10 | 16 | |
| GLM (n = 36) | 9 | 24 | 3 | 26 | 1 | 9 | ||
| INF (n = 220) | 19 | 82 | 119 | 111 | 13 | 31 | 21 | 44 |
| RTX (n = 12) | 7 | 4 | 1 | 6 | 1 | 5 | ||
| SEC (n = 11) | 4 | 7 | 3 | 3 | 2 | 3 | ||
| TCZ (n = 22) | 4 | 14 | 4 | 13 | 9 | |||
| UST (n = 15) | 12 | 3 | 7 | 1 | 1 | 6 | ||
| CT-P13 (n = 13) | 12 | 1 | 3 | 9 | 1 | |||
ABA abatacept, ADA adalimumab, CT-P13 INF biosimilar CT-P13, CZP certolizumab pegol, ECL electrochemiluminescent immunoassay, ELISA enzyme-linked immunosorbent assay, ETN etanercept, GLM golimumab, INF infliximab, NR not reported, RIA radioimmunoassay, RTX rituximab, SEC secukinumab, TCZ tocilizumab, UST ustekinumab